查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363072

曲霉菌病治療市場規模、佔有率、趨勢分析報告：按類型、藥物類別、給藥途徑、給藥配銷通路、地區、細分市場趨勢，2023-2030

Aspergillosis Treatment Market Size, Share & Trends Analysis Report By Type (Allergic, Chronic, Invasive), By Drug Class (Antifungal), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

曲霉病治療市場的成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球曲霉病治療市場規模將達到57.9億美元，2023年至2030年年複合成長率為3.99%。

曲霉菌病感染疾病的罹患率不斷上升，特別是在免疫力缺乏的個體中，刺激了對創新治療方法的需求。醫療技術和藥物開發的快速進步導致引入更有針對性和有效的治療方法，改善患者的治療效果和治療效果。意識和診斷能力的提高有助於早期發現和快速開始治療，進一步增加對各種藥物的需求。現有的治療範例包括除抗生素和皮質類固醇外，也使用唑類抗真菌藥物（例如伊曲康唑和伏立康唑）。

F2G、TFF Pharmaceuticals、Scinexis 和 Pulmocide 等知名公司正在推出創新的治療策略，這些策略有可能重塑侵襲性麴菌病治療的格局。此類候選藥物的成功上市可能對該市場的現有製藥領導者構成重大挑戰。這項挑戰似乎源自於徹底改變既定護理標準並從而為患者提供創新方法的能力。

公司和研究人員目前正在努力評估挑戰並確定可能影響研發 (R&D) 和治療前景的潛在機會。該領域持續配合措施的重點是旨在加強曲霉病應對和管理的創新策略。例如，2022年4月，Palmatrix 宣布恢復其窄譜激酶抑制劑（NSKI）產品組合的全部權利，其中包括 PUR1800。

這項決定是在強生企業創新決定終止與 Palmatrix 先前的授權、開發和商業化協議之後做出的。針對此情況，Pulmatrix 宣布有意繼續進行 PUR1800 的開發。該公司計劃透過正在進行的臨床評估和毒理學研究來繼續推進該化合物的發展。這些努力將加強針對慢性阻塞性肺病（COPD）和其他慢性呼吸道疾病急性惡化的計畫。

曲霉病治療市場報告亮點

  • 按類型分類，過敏性細分市場在 2022 年佔據最大的銷售佔有率。這種成長是由於患病疾病症狀輕微，特別是過敏性支氣管肺麴菌病（ABPA）等疾病，它影響氣喘和囊性纖維化患者。
  • 依藥品類別分類，2022年抗真菌藥物佔最大銷售佔有率。這種成長是由於它對曲霉菌感染的有效性及其作為主要治療選擇的廣泛使用。
  • 根據給藥途徑，口服藥物領域在 2022 年佔據最大的收益佔有率。這種成長歸因於其便利性和患者友好的給藥方法，使其成為醫療保健提供者和患者的首選。
  • 從配銷通路來看，醫院藥房細分市場佔據主導地位，2022年佔有率為47.59%。這一成長歸因於以醫院為基礎的配銷通路在曲霉菌病治療的有效提供和可及性方面發揮的關鍵作用。
  • 2022年，北美將主導市場。這一優勢源於強調該地區先進的醫療基礎設施、充滿活力的研發 (R&D) 努力以及尖端醫療技術的多種要素的綜合作用。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場趨勢及展望
  • 市場動態
    • 曲霉菌病患病患病增加
    • 醫學研究進展
    • 改善識別和診斷
  • 市場抑制因素分析
    • 治療選擇有限
    • 昂貴的治療費用
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第4章 曲霉病治療市場：按類型細分分析

  • 曲霉病治療：2022 年和 2030 年市場佔有率分析
  • 過敏性麴菌病
  • 慢性麴菌病
  • 侵襲性麴菌病

第5章 曲霉病治療市場：依藥物分類分析

  • 曲霉病治療：2022 年和 2030 年市場佔有率分析
  • 抗真菌藥物
  • 其他

第6章 曲霉菌病治療市場：依給藥途徑細分分析

  • 曲霉病治療：2022 年和 2030 年市場佔有率分析
  • 口腔醫學
  • 軟膏
  • 粉末
  • 其他

第7章 曲霉病治療市場：依配銷通路細分分析

  • 曲霉病治療：2022 年和 2030 年市場佔有率分析
  • 醫院藥房
  • 零售藥房
  • 其他

第8章 區域業務分析

  • 2022 年及 2030 年曲霉菌病治療市場佔有率（按地區）
  • 北美洲
    • 北方麴菌病治療市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲曲霉菌病治療市場，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區麴菌病治療市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 拉丁美洲曲霉菌病治療市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • SWOT分析
    • MEA 麴菌病治療市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭形勢

  • 公司分類
  • 策略規劃
  • 2022 年公司市場佔有率分析
  • 公司簡介/名單
    • Pfizer, Inc
    • Merck &Co
    • F2G
    • Novartis AG;
    • Astellas Pharma Inc
    • Bayer AG
    • Mayne Pharma Group Limited
    • PULMATRiX
Product Code: GVR-4-68040-123-2

Aspergillosis Treatment Market Growth & Trends:

The global aspergillosis treatment market size is expected to reach USD 5.79 billion by 2030, registering a CAGR of 3.99% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The rising incidence of aspergillosis infections, particularly among immunocompromised individuals, has spurred the demand for innovative treatment approaches. Rapid advancements in medical technology and drug development have led to the introduction of more targeted and effective therapies, enhancing patient outcomes and treatment efficacy. Improved awareness and diagnostic capabilities contribute to early detection and prompt treatment initiation, further increasing the demand for various drugs. The existing treatment paradigm predominantly relies on the utilization of conventional antifungal drugs such as azoles (such as Itraconazole and voriconazole), in addition to antibiotics and corticosteroids.

Several prominent companies such as F2G, TFF Pharmaceuticals, Scynexis, and Pulmocide are in the process of introducing innovative therapeutic strategies that hold the potential to reshape the landscape of Invasive Aspergillosis treatment. The successful launch of such candidates could pose a substantial challenge to the established pharmaceutical leaders in the market. This challenge would arise from their capacity to revolutionize the established standard of care, thereby offering a transformative approach for patients.

Companies and researchers are currently engaged in evaluating challenges and identifying potential opportunities that could impact the research and development (R&D) and treatment landscape. The ongoing efforts in this field are centered around innovative strategies aimed at addressing and enhancing the management of Aspergillosis. For instance, in April 2022, Pulmatrix announced the restoration of complete rights to its portfolio of narrow-spectrum kinase inhibitors (NSKIs), which includes PUR1800.

This decision came about after the determination by Johnson & Johnson's Enterprise Innovation to terminate the licensing, development, and commercialization agreement previously established with Pulmatrix. In response, Pulmatrix has outlined its intention to proceed with the advancement of PUR1800. The company plans to continue the progression of this compound by conducting continuous clinical assessments and toxicology studies. These endeavors are undertaken to bolster programs focused on acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD) as well as other chronic respiratory conditions.

Aspergillosis Treatment Market Report Highlights:

  • Based on type, the allergic segment held the largest revenue share in 2022, the growth can be attributed to higher prevalence and milder disease presentation, particularly in conditions such as allergic bronchopulmonary aspergillosis (ABPA) affecting asthma and cystic fibrosis patients
  • Based on drug class, the antifungal drug segment held the largest revenue share in 2022, the growth can be attributed to their effectiveness in combating aspergillosis infections and their wide usage as a primary treatment option
  • Based on route of administration, the oral drugs segment held the largest revenue share in 2022. This growth is due to its convenience and patient-friendly administration, making it a preferred choice for both healthcare providers and patients
  • Based on distribution channel, the hospital pharmacy segment dominated the market with a share of 47.59% in 2022. This growth is due to the pivotal role that hospital-based distribution channels play in the effective delivery and accessibility of treatments for aspergillosis
  • North America dominated the market in 2022. This dominance can be attributed to a confluence of factors that underscore the region's advanced healthcare infrastructure, dynamic research and development (R&D) endeavors, access to cutting-edge medical technologies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Drug Class
      • 1.1.1.3. Route of Administration
      • 1.1.1.4. Distribution Channel
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective 1
    • 1.4.2. Objective2
    • 1.4.3. Objective 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing Prevalence of Aspergillosis
    • 3.4.2. Advancements in Medical Research
    • 3.4.3. Awareness and Diagnosis Improvement
  • 3.5. Market Restraint Analysis
    • 3.5.1. Limited Treatment Options
    • 3.5.2. High Treatment Costs
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Aspergillosis Treatment Market: By Type Segment Analysis

  • 4.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
  • 4.2. Allergic Aspergillosis
    • 4.2.1. Allergic Aspergillosis Market, 2018 - 2030 (USD Million)
  • 4.3. Chronic Aspergillosis
    • 4.3.1. Chronic Aspergillosis Market, 2018 - 2030 (USD Million)
  • 4.4. Invasive Aspergillosis
    • 4.4.1. Invasive Aspergillosis Market, 2018 - 2030 (USD Million)

Chapter 5. Aspergillosis Treatment Market: Drug Class Segment Analysis

  • 5.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
  • 5.2. Antifungal Drugs
    • 5.2.1. Antifungal Drugs Market, 2018 - 2030 (USD Million)
      • 5.2.1.1. Azoles
      • 5.2.1.2. Echinocandins
      • 5.2.1.3. Polyenes
      • 5.2.1.4. Allylamines
      • 5.2.1.5. Others
  • 5.3. Others
    • 5.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Aspergillosis Treatment Market: Route of Administration Segment Analysis

  • 6.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
  • 6.2. Oral Drugs
    • 6.2.1. Oral Drugs Market, 2018 - 2030 (USD Million)
  • 6.3. Ointments
    • 6.3.1. Ointments Market, 2018 - 2030 (USD Million)
  • 6.4. Powders
    • 6.4.1. Powders Market, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Aspergillosis Treatment Market: By Distribution Channel Segment Analysis

  • 7.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
  • 7.2. Hospital Pharmacy
    • 7.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.3. Retail Pharmacy
    • 7.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.4. Others
    • 7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Aspergillosis Treatment Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. U.S. Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Canada Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. UK Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Germany Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. France Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Italy Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Spain Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Denmark Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Sweden Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Norway Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Japan Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. China Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. India Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Australia Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Thailand Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. South Korea Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Brazil Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Mexico Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Argentina Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. South Africa Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Saudi Arabia Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. UAE Aspergillosis Treatment Market, 2018 - 2030 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Kuwait Aspergillosis Treatment Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Company Profiles/Listing
    • 9.4.1. Pfizer, Inc
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Merck & Co
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. F2G
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Novartis AG;
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Astellas Pharma Inc
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Bayer AG
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Mayne Pharma Group Limited
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. PULMATRiX
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 3 Global aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 Global aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 Global aspergillosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 8 North America aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 North America aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 North America aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 12 U.S. aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 13 U.S. aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 U.S. aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 17 Canada aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Canada aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Canada aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 21 Europe aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Europe aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Europe aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 25 UK aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 26 UK aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 UK aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 Germany aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 30 Germany aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 Germany aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 France aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 34 France aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 France aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 France aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Italy aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 38 Italy aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Italy aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Italy aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Spain aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 42 Spain aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Spain aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Spain aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 46 Denmark aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Denmark aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 50 Sweden aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Sweden aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Norway aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 54 Norway aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Norway aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Norway aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 63 Japan aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 64 Japan aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 65 Japan aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 Japan aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 China aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 68 China aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 69 China aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 China aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 India aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 72 India aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 India aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74 India aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Australia aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 76 Australia aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Australia aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 Australia aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Thailand aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 80 Thailand aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 81 Thailand aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Thailand aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 84 South Korea aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 South Korea aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 South Korea aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Latin America aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 88 Latin America aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Latin America aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America aspergillosis treatment market, by country, 2018 - 2030 (USD Million
  • Table 92 Brazil aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 93 Brazil aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 94 Brazil aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Brazil aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96 Mexico aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 97 Mexico aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 98 Mexico aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 99 Mexico aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Argentina aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 101 Argentina aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 102 Argentina aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103 Argentina aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109 Middle East & Africa aspergillosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 110 South Africa aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 111 South Africa aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 112 South Africa aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 113 South Africa aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 117 Saudi Arabia aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 118 UAE aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 119 UAE aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 120 UAE aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 121 UAE aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 122 Kuwait aspergillosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 123 Kuwait aspergillosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 124 Kuwait aspergillosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 125 Kuwait aspergillosis treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Aspergillosis treatment market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market Trends & outlook
  • Fig. 10 Market driver relevance analysis (Current & future impact)
  • Fig. 11 Market restraint relevance analysis (Current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global aspergillosis treatment market: By Type movement analysis
  • Fig. 16 Global aspergillosis treatment market, for allergic aspergillosis, 2018 - 2030 (USD Million)
  • Fig. 17 Global aspergillosis treatment market, for chronic aspergillosis, 2018 - 2030 (USD Million)
  • Fig. 18 Global aspergillosis treatment market, for invasive aspergillosis, 2018 - 2030 (USD Million)
  • Fig. 19 Global aspergillosis treatment market: Drug Class movement analysis
  • Fig. 20 Global aspergillosis treatment market, for antifungal drugs (Azoles, Echinocandins, Polyenes, Allylamines, Others) 2018 - 2030 (USD Million)
  • Fig. 21 Global aspergillosis treatment market, for others, 2018 - 2030 (USD Million)
  • Fig. 22 Global aspergillosis treatment market: Route of Administration movement analysis
  • Fig. 23 Global aspergillosis treatment market, for oral drugs, 2018 - 2030 (USD Million)
  • Fig. 24 Global aspergillosis treatment market, for ointments, 2018 - 2030 (USD Million)
  • Fig. 25 Global aspergillosis treatment market, for powders, 2018 - 2030 (USD Million)
  • Fig. 26 Global aspergillosis treatment market, for others, 2018 - 2030 (USD Million)
  • Fig. 27 Global aspergillosis treatment market: Distribution Chanel movement analysis
  • Fig. 28 Global aspergillosis treatment market, for hospital pharmacies, 2018 - 2030 (USD Million)
  • Fig. 29 Global aspergillosis treatment market, for retail pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Global aspergillosis treatment market, for other pharmacies, 2018 - 2030 (USD Million)
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional outlook, 2022 & 2030
  • Fig. 33 Global aspergillosis treatment market: Region movement analysis
  • Fig. 34 North America aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 UK aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 France aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 China aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 India aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Mexico aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE aspergillosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait aspergillosis treatment market, 2018 - 2030 (USD Million)